LINK WILLIAM J PHD 4

What Happened
William J. Link, Ph.D., a director of Tarsus Pharmaceuticals (TARS), was awarded equity on 2026-06-25 consisting of a 3,837‑unit annual stock option grant and two restricted stock unit (RSU) awards totaling 3,223 RSUs (2,417 RSUs and 806 RSUs). The reported price for each grant is $0.00 because these are equity awards; no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-25; Form 4 filed 2026-06-29 (filed within customary two business days).
• Awards: 3,837 (option award, footnote F1) + 2,417 RSUs (F3) + 806 RSUs (F4) = 7,060 total units. Reported acquisition code: A (award/grant).
• Reported price: $0.00 for each award (standard for grants). No sale or open‑market purchase occurred.
• Vesting: The 3,837 option vests in full one year after grant (F1). The 2,417 RSUs vest in full on the one‑year anniversary (F3). The 806 RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027 (F4). All vesting is subject to continuous service as a non‑employee director.
• Shares owned after transaction: not specified in the provided data from the filing.
• Transaction type/implication: award/grant (neutral routine director compensation), not an open‑market purchase or sale.

Context
RSUs are contingent rights to receive common stock at vesting; options are derivative rights to purchase stock under plan terms. These grants are routine director compensation disclosed on Form 4 and do not by themselves indicate an intent to buy or sell stock immediately.